Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?

Nature Clinical Practice Gastroenterology & Hepatology volume 1, pages 24–25 (2004)Cite this article

boxed-textAfdhal NH et al. (2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126: 1302–1311

Some patients with difficult-to-treat HCV infection could benefit from epoetin alfa to maintain ribavirin dose when receiving antiviral therapy

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Manns MP et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965

    Article  CAS  Google Scholar 

  2. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982

    Article  CAS  Google Scholar 

  3. Lin CC et al. (2004) Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 44: 265–275

    Article  CAS  Google Scholar 

  4. Gish R et al. (2004) Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients. J Hepatol 40: 1

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Ruth Kirby, Research Highlights Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. viral hepatitis group leader Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

    Heiner Wedemeyer

  2. Director and Chairman at the Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

    Michael P Manns

Authors
  1. Heiner Wedemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael P Manns.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wedemeyer, H., Manns, M. Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. Nat Rev Gastroenterol Hepatol 1, 24–25 (2004). https://doi.org/10.1038/ncpgasthep0016

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0016

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing